Let’s jump right in and start in the 145th General Assembly: 2009-10. 

Two bills signed into law in 2009-10 exemplify a bridge between physical infrastructure and technological infrastructure:

  • Senate Bill 176 (2009) – “[E]xtends the deadline for the Universal Tamper-Resistant Prescription Pad Committee to establish a statewide tamper-resistant prescription form with specific criteria to eliminate or significantly reduce prescription fraud.”
  • Senate Bill 235 (2010) – Prescription Monitoring Program – “[P]rogram for the monitoring of prescribing and dispensing Schedule II, III, IV, or V controlled substances and other drugs of concern by the Office of Controlled Substances of the Division of Professional Regulation. It requires dispensers to submit certain information regarding the dispensing of controlled substances. That information is compiled into a database that can be accessed by physicians and other prescribers to provide them additional information about their patient’s history of controlled substance use.”

While tamper-resistant prescription pads have been an important tool at curbing diversion, it is Senate Bill 235 which was truly seminal legislation for Delaware. The Prescription Monitoring Program (“PMP” or, in many states, “PDMP”) has been a foundation for opiate policy since its creation.

If you are not familiar with the basic functioning of a PMP, much has been written on their history dating back to 1918. The basic idea is that all data from prescriptions and dispensing (usually from a pharmacy) is collected in a single place so that diversion of controlled substances can be detected and prevented. A classic example is “doctor shopping” where one patient receives several prescriptions for one real (or fake) injury. Then fills those scripts at several different pharmacies to fill their addiction or to sell.

From this basic description, one can readily see several policy questions. The original sponsors of the bill saw some of them as well. The PMP’s law is now codified in 16 Del.C § 4798 and states the PMP, “serves as a means to promote public health and welfare and to detect the illegal use of controlled substances. The Delaware Prescription Monitoring Act shall have the dual purpose of reducing misuse and diversion of controlled substances in the State while promoting improved professional practice and patient care.” Importantly, and a source of ongoing policy tension, section 4798(c)(2) further states that the PMP may be used to “[a]ssist law enforcement to investigate illegal activity related to the prescribing, dispensing, and consumption of controlled substances or drugs of concern.”

As we move forward through the years, we’ll be taking a close look at how the PMP has evolved and explore the use and efficacy of this tool. Be sure to check back in as we look at the 146th General Assembly.

General Assembly: 2011-12

In part one of this series, we left off with the creation of the Prescription Monitoring Program (PMP) in the 145thGeneral Assembly. As you can see from the chart, coming into the 146th General Assembly, the curve is rising. As a caution, note that these data sets are retrospective and many of the tools for tracking were not yet readily available. Delaware policymakers are experiencing an uptick in 2011, but probably see 2008 data which is not too much different from 2002. Thus, a problem persists, but to a policymaker the alarms aren’t yet going off. And, you may recall, this is also the time that synthetic drugs were the news of the day. Not to be either hyperbolic or blasé, the peak of this hype was probably May 2012 with the “Miami Cannibal” or “Zombie Attack” – a nude man high on “bath salts” bit off the face of homeless man – and the world watched.[4]

As can be expected, in 2011 and 2012, Delaware, along with many other states, passed legislation in reaction to the proliferation of “synthetic” or “designer” drugs: House Bill 30 (2011) & Senate Bill 160 (2012) – Banning Synthetic Drugs (“Bath Salts”, “Spice,” “K2,” “Genie,” “Yucatan Fire,” “Sence,” “Smoke,” “Skunk,” and “Zohai”) and their analogues.

This is also the year that Delaware, after several attempts, passes its Delaware Medical Marijuana Act, SB 17(2011). Marijuana has played a fascinating policy role as a foil to opiates. Marijuana is still, as of the time of this writing, a Schedule I drug. When Delaware passed its bill, President Obama’s administration was giving unclear signals on federal enforcement, delaying, but not preventing, the build out of Delaware’s program.[5] During the (ongoing) marijuana legalization debate in 2017 and 2018 – while the Trump Administration promised a crackdown[6] – Delaware advocates directly tied the topics together, stating that marijuana legalization would curb adverse effects of the opiate crisis.[7]

Setting that aside, Delaware takes a run at a still-common problem: what do to with leftover prescription drugs? Delaware introduces, but does not pass, HB 206 (2011), giving the “Board of Pharmacy authority to establish standards and procedures for the collection, destruction, return and redistribution of previously dispensed medications. The drug collection program must comply with all applicable local, state, and federal laws and regulations, and shall be done under a licensed health care professional’s supervision. In addition, the DEA and the Office of Controlled Substances shall implement security measures.” The major complicating factor here is that the rules around this topic are substantially federal; the Drug Enforcement Agency in particular, which has, over the years, created avenues for takeback programs.[8]

Lastly in this session, is SB 278 (2012) which sought to:

  • Codify the Controlled Substance Advisory Committee;
  • Make clear the powers of the Secretary of State – which oversees licensing in Delaware – regarding controlled substance registration and emergency removal; and
  • Require PMP Checks “[w]hen a dispenser has a reasonable belief that a patient may be seeking a controlled substance listed in Schedule II, III, IV or V for any reason other than the treatment of an existing medical condition, the dispenser shall obtain a patient utilization report regarding the patient for the preceding 12 months from the Prescription Monitoring Program before dispensing the prescription.”

Senate Bill 278 failed to move forward this session, but we’ll pick up the important policy thread it introduces – mandatory use of the PMP – in the next post.

General Assembly:  2013-14

Before we wrap on the 145th, however, legislation is not the only enforcement tool in play. The Board of Medical Licensure and Discipline, which sits under the Secretary of State and his Division of Professional Regulation, creates “Regulation 18” in this window. While the Physician Advisory Committee for Controlled Substances also created pain guidelines in 2012, these regulations started to give the regulators teeth by adopting the Federal of State Medical Board’s “Model Policy for the Use of Controlled Substances for the Treatment of Pain.”

This kicks off a debate that continues to this day: the best and most responsible way to change prescriber habits and culture. Guidelines are an attempt by the profession to self-regulate through driving standard of care. Regulations leverage the state’s authority in licensing to mandate change through enforcement. An issue we’ll revisit in another post!

The 147th General Assembly is two things. First, it’s busy. Second, it’s a game-changer. These are the years that patient advocacy groups show up in Dover and they come with a few messages. First, that the people dying are their family members. Mothers, fathers, sons, daughters, even grandparents are falling victim in the opiate crisis. Second, and related, that it’s time to get addicts, as patients suffering from a disease, not criminals, the help they need.

Before we jump into these Patient-Victim bills let’s pick up the thread we left off with in the second post and a bill that didn’t make it to the Governor’s desk in time in the 146th General Assembly. Senate Bill 278 (2012) is reintroduced as Senate Bill 59 (2013). It still includes the Controlled Substance Advisory Committee; the Secretary of State’s powers on Controlled Substance Registration requirements & removal; and mandatory PMP checks upon reasonable believe a patient may divert them. It also includes some important additions and tweaks. It adds two new licensee types – “Chemical Dependency Professional” and “Licensed Professional Counselor of Mental Health.” It also adds a deadline, January 1, 2014, for mandatory PMP registration for Controlled Substance Registration holders.

However, that’s not all the new bill does. Perhaps most importantly for the changes, it introduces to legislative hall two new issues. First and foremost, the question of data access. It liberalizes access to PMP reports for these new licensees and the Chief Medical Examiner. For the latter in particular, this is a signal that Delaware is starting to try and connect data points all the way to the time of unfortunate and untimely overdose victim deaths.

Second, reflects a recognition that the work flow changes in different care settings. To this, the legislation adds a “Dispenser” carve out from the PMP checks for immediate medical administration in an emergency department. As you might imagine, the frantic pace and high stakes of an emergency setting have different administrative burden considerations.

Perhaps the biggest demarcation this session is the clear effect victim families are having in legislative hall. Organizations like Attack Addiction enter their advocacy infancy, partnering with organizations like the Medical Society of Delaware to pass Senate Bill 116 (2013), the “Kristen L. Jackson & John M. Perkins, Jr. Law” aka “Good Samaritan 911 Law.” This legislation critically sends the first legislative signal to the broader addiction victim community that the government will prioritizing assistance in an emergency. No longer should overdose victims be pushed out of moving cars in front of emergency departments, their friends fearful of prosecution by law enforcement.[9]

Springboarding from their fast success in a single-year introduction and passage of the Good Samaritan Law, the advocacy community shifts its focus to the overdose-reversing drug, Naloxone. Senate Bill 219 (2014) “[a]llow[s] DHSS to create a community-based program that will put Naloxone into the hands of friends, family, and maybe service providers at no or low cost.” House Bill 388 (2014) creates a system so that “peace officers who have completed a DHSS approved training course [may] receive, carry, and administer the drug naloxone.” It’s not fair to say that all peace officers were skeptical of carrying naloxone, but this was certainly an area of friction as law enforcement retooled from decades of “war on drugs” posture.

Of course, the legislature was still looking at the drugs themselves, too. Specifically, potential diversion points by person who had access to patients at their most vulnerable times. House Bill 154 (2013) and Senate Bill 119(2013) respectively created a felony of medication diversion in a facility, classifying it as ‘Abuse,’ and created safe disposal mechanisms for controlled substances after hospice care.

These same bills also put a spotlight on the prescribers themselves. Controlled substances have extra regulatory layers before they can be prescribed. Federal law requires a DEA license and state law requires a Controlled Substance Registration (CSR). House Bill 154 required that holders of CSR had to take continuing medical education courses around safe prescribing as an attempt to re-educate the prescribing community to make them more aware of the crisis and thoughtful of how and when they used controlled substances. Senate Bill 119 created a cap on non-pharmacy dispensing at a 72-hour supply. That is, if a patient is getting their prescription through a pharmacy, that they could only get a very limited amount of medication.

As the last bill we’ll look at, and theme that’s introduced, the legislature takes its first real stab at an important bottleneck: payment. House Bill 164 (2013) “requires health insurers issuing large group policies to provide a minimum of 30 consecutive days of inpatient care for serious mental illnesses and drug and alcohol dependencies in order to increase the likelihood of long-term success.” Addiction care is expensive and while the bill fails to even get out of committee, it marks the beginning of the legislature starting to think about the financial repercussions of the issue and opening payment avenues for treatment.

General Assembly: 2015-16

Legislatively, the 148th catches its breath after the policy sprint of the 147th. However, at this point, they are not the only policy body looking at the issue. As the trend lines continue to climb, the Secretary of State, specifically through the Division of Professional Regulation and in concert with the Attorney General, regulations are crafted to put downward pressure on prescribers.

But first, what does the legislature get up to in this window? The first thing is a cleanup with Senate Bill 8 (2015) which “[c]reates an exception for veterinarians and methadone clinics from dispensing more than 72 hours of a controlled substance.”

Next, it puts some focus back on the criminal justice system. Although the shift of addiction into public health continues from the 147th in the larger community, law enforcement is still deeply involved in issue. Senate Bill 154(2015) extends jurisdiction for possession, use, or consumption of controlled substances to Court of Common Pleas to add some bandwidth to the system. House Bill 239 (2016) re-establishes the crime of “Drug Dealing – Resulting in Death” as more powerful drugs like fentanyl proliferate. The idea being that it pressures the drug dealer to better inform addicts of the increased concentration of the product on the street.

As a footnote, Senate Bill 143 (2016) surprisingly opens up a new prescription pad, allowing optometrists to prescribe limited quantities of controlled substances. A counter-move to the push down on the opiates flowing into the community through prescribers.

Easily the most notable accomplishment of the legislature in this window is the creation of the Overdose Death Review Commission in Senate Bill 174 (2016). The purpose to reverse engineer overdose deaths to inform policy and find problem areas. Easier said than done, however. The policies and barriers layered inside of this are many. As an illustration of these difficulties, even though the legislation was signed into law in 2016, it wasn’t until mid-2018 that the body was actually reviewing cases.[10]

Why did it take so long?

First, there’s no question that addiction carries a continued deep stigma. Federal policy has understood this for a while and a not-well-known law, 42 CFR part 2, adds another layer in addition to the better-known HIPAA protections for patient data regarding substance use disorders. Second, the data necessary to get a longitudinal view of what led to an overdose death is stored in many pockets and pools between care settings. Some of which require subpoenas to enter. But the Commission did finally get to work.

Back to the regulators as we round out the 147th: the Secretary of State runs out of patience waiting for prescriber habits to change and creates “Regulation 9” in this window. Over objection from the Medical Society that “specialty-specific prescribing guidelines as opposed to ‘reflexively’ enacted, ‘one-size-fits-all,’ restrictive regulations” should be preferred, regulations go into effect for all prescribers of controlled substances that create a default seven day prescribing cap, with a documentation pathway for a longer period. While healthy debates continue over whether the process should have been regulatory-driven or guideline-driven, a year after enactment prescriptions were down 14% and dispensing down 18%.[11]

General Assembly:  NOW

It goes without saying that the Attorney General has neither a vote in the General Assembly nor does the office sign bills into law. However, these next two years are undoubtedly driven by then-Attorney General Matt Denn. However, legislator-led initiatives more-than-robustly supplemented these efforts.

“The Denn Bills” were a set of three:

  • Senate Bill 41 (2017) – Expanded insurance coverage for in-patient drug and alcohol dependencies for as long as medically necessary. Removal of prior authorization for five days of emergency treatment. [Recall HB 164 of 2013]
  • House Bill 100 (2017) – Allows the Department of Justice to provide legal assistance where appropriate to persons seeking benefits from the state’s Medicaid program, traditional health plans, or from employer-funded health benefit plans
  • House Bill 91 (2017) – PMP Advisory Committee “established to provide input, advice, and guidance to the Office of Controlled Substances regarding the maintenance of the PMP” by “[d]evelopment of specific criteria for referring prescription monitoring information to the Advisory Committee for consideration of notification of law enforcement or professional licensing agencies.”

In the context of the third bill in particular, it’s worth noting House Bill 458 along the way quickly. While it ultimately did not become law, we re-highlight our previous comments on this bill because the law emphasized the tension between law enforcement and public health’s use of the Prescription Monitoring Program.

While Delaware was not short on policy bodies making suggestions for how to address the continued climb of addiction, the legislature blessed two in particular. The first, through

House Bill 220 (2018) – which codified the Prescription Drug Action Committee, a partnership committee between the state and the Medical Society, as the Addiction Action Committee. The second, Senate Bill 111, established the Behavioral Health Consortium [under Lt. Governor Hall-Long]. The consortium is an organization we’ll talk about in more depth in our next and last post in this series.

Learning in part as the Overdose Fatality Review Commission ran into barriers, as mentioned in a previous post, the legislature became more intentional in connecting the different pools of data. House Bill 211 (2017) allowed PMP data access for the Drug Overdose Fatality Review Commission. Senate Bill 206 links patient overdose data collected by the Office of Emergency Medical Services or the Office of the State Epidemiologist with data in the Delaware Prescription Monitoring Program. This bill also allowed created the pathway for prescriber and dispenser identified data to flow to the PMP Advisory Committee and the Addiction Action Committee to advance their efforts.

Speaking of coordinating, Delaware passed first-in-the-nation legislation in the form of House Bill 440 (2018) which allowed DHSS to establish an overdose system of care. One of the many beauties of Delaware is that necessary stakeholders can physically fit around the table and coordinate efforts. It had done so before for both stroke and emergency care, and now it decided to do so again to address this public health crisis.

Lastly, a fascinating group of bills represent an ongoing arc of a thought process on how to create an Opiate Fund to better pay for some of the necessary state efforts. It first appeared as House Bill 250 (2017) which was a 10% tax on the “first sale” of opioids in Delaware and directed the money to the general fund. It failed in Committee, but sparked offshoot bills.

The next, House Bill 358 (2018) was a more nuanced 10% tax on “first sale” with proceeds directed to addiction treatment and programming. It failed to get traction as Senate Bill 176 (2018) became the policy-driving bill on this front. It hoped to create a Prescription Opioid Impact Fund funded by a Prescription Opioid Impact Fee assessed quarterly in the amount of $0.01 per MME, the morphine milligram equivalent. While it didn’t obtain passage, the robust conversation will certainly continue.

Lastly we’ll mention in this post – and this isn’t even all of what happened this session![12] – the legislature passed Senate Bill 225 (2018) which opens up pain patients’ access to non-opiate back pain treatments such as PT & Chiropractic.

150th General Assembly – What’s to Come?

While opiate policy in the 149th was driven by the Attorney General, the 150th will undoubtedly be led by Lt. Governor Hall-Long’s Behavioral Health Consortium and its efforts which are soon to come to fruition.

What’s the power of the Consortium? Pre-Consortium, it was nearly impossible for one hand to know what another hand was doing. We can’t even say “left hand and right hand” since a cursory look through Delaware Policymaking Bodies number over a dozen.[13] The Consortium didn’t replace those bodies, but instead coordinated them (with the blessing of the Governor, of course).

The Consortium also recruited help. For example, it not only produced its own recommendations, but organizations turned their focus to Delaware. For example, Pew Charitable Trusts put a team on the ground in Delaware at the request of the Consortium. It comprehensively conducted interviews to identify strengths, weaknesses, and opportunities. These recommendations are expected any day and will undoubtedly contain many action points.

Of course, there will undoubtedly continue to be involvement with the new Attorney General, Kathy Jennings, as her office continues to push against opiate manufacturers. While many predict the collective state lawsuits to result in Tobacco Settlement 2.0, this is not a foregone conclusion.[14]

While the overdose system of care brings a lot of potential for coordination of the resources Delaware has, there remain challenges.[15] Access to local addiction treatment both in facilities and funding, continue to be a barrier.[16] If a funding stream can be found – although the path Delaware was taking a hard look at in the 149th appears narrow[17] – then it could be directed to local services and even services like MAT in our prisons.

No doubt that with fifteen new faces among our sixty-two legislators, new ideas will emerge.

[1] Adapted from a Continuing Legal Education Course, “The Opioid Epidemic and the Law: Developments in Pain Management and Treatment, Regulations, and their Legal Impacts” – Delaware State Bar Association, Sept. 26, 2018

[2] “Delaware loses 39 lives in deadliest month ever from drug overdoses,” Brittany Horn, Delaware News Journal, Sept. 11, 2018 available at https://www.delawareonline.com/story/news/local/heroindelaware/2018/09/11/delaware-sees-deadliest-month-yet-drug-overdoses/1254461002/.

[3] “Delaware overdose deaths could top 400 in 2018,” Mark Eichmann, WHYY, January 1, 2019 available at https://whyy.org/articles/delaware-overdose-deaths-could-top-400-in-2018/.

[4] See, e.g., “Face-Eating Attack Possibly Prompted by ‘Bath Salts,’ Authorities Suspect,” Seni Tienabeso, ABC News, May 29, 2012 available at https://abcnews.go.com/US/face-eating-attack-possibly-linked-bath-salts-miami/story?id=16451452.

[5] “What is President Obama’s Problem with Medical Marijuana,” Michael Scherer, Time, May 3, 2012, available athttp://swampland.time.com/2012/05/03/what-is-president-obamas-problem-with-medical-marijuana/.

[6] “Sessions suggests Trump admin could stamp out legal pot,” Eli Watkins, CNN, Jan 10, 2017 available at https://www.cnn.com/2017/01/10/politics/jeff-sessions-donald-trump-marijuana/index.html

[7] “Marijuana is safer than opioids. So why is it illegal?.” Richard Jester, Delawareonline, Feb 15, 2018, available at https://www.delawareonline.com/story/opinion/contributors/2018/02/15/marijuana-safer-than-opioids-so-why-illegal/337709002/.

[8] See “Where and How to Dispose of Unused Medicines,” DEA,  https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm101653.htm

[9] See, e.g., “OD Victims being dropped off at ER doors as helpers flee,” Linda Marz, Mansfield News Journal, Aug. 30, 2016 available at https://www.mansfieldnewsjournal.com/story/news/local/in-depth/overdosed/2016/08/30/od-victims-being-dropped-off-er-door-helpers-flee/88610820/.

[10] “Data-sharing struggles slow Delaware commission’s review of fatal overdoses,” Brittany Horn, News Journal, July 15, 2018 available at https://www.delawareonline.com/story/news/local/heroindelaware/2018/07/15/delaware-fatal-drug-overdose-commission-addiction/782829002/.

[11] “One year after new regulations issued, Delaware opioid prescriptions and quantities dispensed continue to drop,” Department of Justice, Apr. 29, 2018 available at https://news.delaware.gov/2018/04/19/delaware-opioid-prescriptions-quantities-dispensed-continue-drop/.

[12] HB 331 (2018) – Practitioners to obtain consent from a minor’s parent or guardian prior to prescribing Benzodiazepines and Hypnotics. HB 369 (2018) – Falsification of Medical Records. SB 44 (2017) – Mandatory PMP registration for all CSR’s within 90 days.  SB 48 (2017) – Pharmacist immunity for dispensing naloxone. SB 109 (2018) – Extending SB41 to Medicaid.

[13] General Assembly

Secretary of State & Division of Professional Regulation

Prescription Monitoring Program

Prescription Monitoring Program Advisory Committee

Controlled Substance Registration

Board of Pharmacy

Board of Medical Licensure & Discipline

Office of Controlled Substances

Controlled Substance Advisory Committee

Department of Health & Social Services

Division of Public Health

Overdose Death Commission

Addiction Action Committee

Behavioral & Mental Health Consortium

[14] See, e.g., “Opioid Lawsuits Look More Like A Tobacco Settlement Every Day,” Bruce Japsen, Aug 25, 2018, Forbes available at https://www.forbes.com/sites/brucejapsen/2018/08/25/opioid-lawsuits-looking-more-like-tobacco-settlements-every-day/#6e1609e04f4f.

[15] “Gov. Carney signs legislation establishing nation’s first overdose care system,” Zoe Read, WHYY, Sept. 11, 2018 available at  https://whyy.org/segments/gov-carney-signs-legislation-establishing-nations-first-overdose-care-system/.

[16] “Delaware’s recovery high school contingent on state funding,” Amy Cherry, WDEL, Apr. 6, 2018 available at https://www.wdel.com/news/delaware-s-recovery-high-school-contingent-on-state-funding/article_c4047780-384f-11e8-998c-072975553eb8.html.

[17] “New York law that forces opioid makers and distributors to pay surcharges is ruled unconstitutional,” Ed Silverman, Stat News, Dec. 20, 2018 available at https://www.statnews.com/pharmalot/2018/12/20/new-york-opioid-law-unconstitutional/.